Our study therefore bridges two key areas of cancer therapy: the use of anti-mitotic chemotherapeutics for the treatment of several types of cancer (where a clear understanding of the factors determining patients’ response is still lacking) and the long-standing, yet largely unsuccessful efforts to treat tumours harbouring mutant KRAS, which account for 20–25% of all human cancers. The gene discussed is KRAS; the disease is neoplasm.